"Pharmaceutical Headline Jun" is on the verge of being approved for the global mRNA pharmaceutical panorama.

(2020/08/10) How "fire" is there in the field of gene/cell therapy under the outbreak? Global mRNA pharmaceutical panorama; retail pharmacy antihypertensive drug TOP10, two major domestic brands lit up ... (Click on the title to obtain the original text) "Pharmaceutical first time" Beda Pharmaceuticals ALK inhibitor NSCLC Phase III clinical reached the main endpoint of Beda Pharmaceutical Holdings subsidiary Xcovery Holdings at the World Lung Cancer Congress released its next generation of ALK inhibitor enchaine hydrochloride and the same drug Pfizer Xalkori comparison of the International Multi-Center Phase 3 clinical study results.
results showed that the mid-progress life of patients with ALK-positive non-small cell lung cancer treated with enchained was significantly longer than that of patients treated with ketamine, reaching the primary endpoint.
: The drug may become the first Chinese-led globally marketed lung cancer target innovative drug.
"Insight database" is day clear "fluvys group injection" first imitation is about to be approved recently, is day sunny new class 4 generic drugs "fluorovis group injection" listing application into the approval state, is expected to be approved to become the first imitation in China.
: Whether from the first imitation advantage, or good policies, or technical barriers, the fluorovis group can bring new growth forces to the positive day.
there is a "fire" in the field of gene/cell therapy under the M.A. outbreak? In the first half of 2020, funding for the global field of regenerative medicine (including gene therapy, gene-engineered cell therapy, cell therapy, and tissue engineering) reached US$10.7 billion, exceeding the total funding for the whole of 2019.
expects a record amount of funding for the whole of 2019.
, companies dedicated to developing regenerative therapies have broken the 1000 mark for the first time! Headline: Several regenerative medicine treatments are expected to be submitted for regulatory applications and approval in the second half of this year.
the eight o'clock health news, why Chinese love to be hospitalized? According to the 2019 Statistical Bulletin on The Development of Health and Health in China, published recently by the Health And Health Commission, the hospitalization rate in Chinese hospitals is still rising, and has reached 19%.
the timeline, hospital admissions in China have risen by 90 per cent in the past decade.
hospitalization rates in China are 40 percent higher than the international average, according to a 2019 study published in The Lancet.
: Behind a decade-long doubling of hospitalization rates is a loophole in the system that has damaged not only health-care funding that is nearing the bottom, but also the most serious patients who should be hospitalized but not hospitalized.
Pharmaceuticals Global mRNA Pharmaceutical Panorama Pfizer, Lilly, Sanofi, GSK, AstraZenewan and other well-known pharmaceutical companies have entered the mRNA drug field through cooperation with Mderna, CureVac or BioNTech and other mRNA drug companies.
, most pharmaceutical companies focus on the layout of mRNA therapeutic products, preventive vaccines with new crown vaccines, influenza vaccines in the majority.
: After 20 years of development, mRNA technology has gradually lifted the veil of mystery, and mRNA drugs have become a new darling in the field of biopharmaceuticals.
"Minet" retail pharmacy antihypertensive drug TOP10 two domestic brands bright rice net data show that in 2019 China's urban retail pharmacy terminal antihypertensive drug market size of more than 14 billion yuan, of which TOP10 products total sales of more than 8.5 billion yuan, phenyl sulfonate amphetamine flat tablets, benzoic acid lamine flat tablets, nitrosin flat release tablets annual sales of more than 1 billion yuan.
Headline bacteria: retail pharmacy antihypertensive market is mainly dominated by multinational enterprises, TOP10 brand has 8 for foreign brands, 2 for domestic brands, respectively, Shi Huida's benzoic acid lamine chloride tablets and China Resources double crane compound polypyridine butterfly tablets.
.